ClinicalTrials.gg
CompletedNCT05109832Updated Sep 16, 2025

A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects

A Phase 1 interventional study of 14C-IMP4297 in Solid Tumor, sponsored by Impact Therapeutics, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects

Read the detailed description

Study design A Phase I, single-center, open-label, single arm study is designed to evaluate Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects.

6-8 subjects are planned to be enrolled (at least 6 subjects complete the study)

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Impact Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteers must meet all of the following inclusion criteria to be included in the study:

    1. Volunteers must fully understand the objective, nature, methods and possible adverse reactions of the trial, volunteer to be volunteers, and sign an form before the start of any study procedures, and at the same time guarantee that the volunteers will personally participate in the study during any procedures.
    2. Chinese healthy male volunteers aged between 18 and 55 (including cut-off values) at the time of screening.
    3. Volunteers with a (BMI) of 18.0-28.0 kg/m2 (including cut-off values), and a body weight of ≥ 50.0 kg.

Exclusion criteria

Exclusion Criteria:

  • Volunteers who meet any of the following criteria cannot be included in this study:

    1. Diseases with abnormal clinical manifestations that need to be excluded, including but not limited to diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bones.
    2. A history of allergic diseases (including drug allergies and food allergies, etc.).
    3. A history of any gastrointestinal diseases that will affect drug absorption such as dysphagia, irritable bowel syndrome, and inflammatory bowel disease; active hemorrhoids or perianal diseases accompanied by regular/current blood in the stool; habitual constipation or diarrhea.
    4. Those who have undergone surgery within 3 months before screening, or who plan to undergo surgery during the study period, and those who have undergone surgery that will affect drug absorption, metabolism, or excretion.
    5. Those who cannot tolerate venipuncture, and those who have a history of needke sickness and blood phobia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C-IMP4297

    In this study, one 100 mg dose of 14C IMP4297 Oral Suspension, 100 mg (100 μCi).

    Drug: 14C-IMP4297

Interventions

  • Drug14C-IMP4297

    14C marked IMP4297

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum concentration)

    peak concentration

    Time frame: 3 months

  2. Tmax

    Time to peak

    Time frame: 3 months

  3. AUC0-inf (Area under the curve from time 0 to infinity)

    area under the curve from time zero to infinity

    Time frame: 3 months

  4. AUC0-last (Area under the curve from time 0 to the last time with quantifiable concentration)

    AUC0-last area under the curve from time zero to the time with the last quantifiable concentration

    Time frame: 3 months

  5. t½ (Elimination half-life)

    elimination half-life

    Time frame: 3 months

  6. CL/F (Apparent clearance)

    apparent clearance

    Time frame: 3 months

  7. Vz/F (apparent volume of distribution )

    apparent volume of distribution

    Time frame: 3 months

  8. urine and fecal samples for quantification analysis

    Assessment of recovery percent in urine and feces by liquid chromatography-radiochemical-detection。 Get Percent (%) of each radiolabeled drug-related material will be determined in urine and feces

    Time frame: 3 months

  9. After oral administration of [14C] IMP4297 in healthy volunteers, radioactive metabolite spectrogram are obtained to identify the main metabolites and clarify the main biotransformation pathways.

    Proportion of different metabolites,Assessment of metabolites (metabolites identification and main metabolites) in plasma/urine/faeces by liquid chromatography-radiochemical-detection

    Time frame: 3 months

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Nov 5, 2021
StartActual
Oct 9, 2021
Primary completionActual
Dec 6, 2021
CompletionActual
Dec 6, 2021
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05109832
Lead sponsor
Impact Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 5, 2021
Start date
Oct 9, 2021
Primary completion
Dec 6, 2021
Completion
Dec 6, 2021
Last update
Sep 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion